Primer: China Medical System (867 HK) - Aug 2026
Transition to Innovative Portfolio Driving Growth: China Medical System (CMS) is navigating China's evolving pharmaceutical landscape by...
96 Views
China Medical System (867 HK) – From an 8 to a 16 FPE
The gap valuation between US drug companies and CMS has largely closed. Earnings outlook is largely flat since initiation, implying the share price...
400 Views
Primer: China Medical System (CMS SP) - Apr 2026
China Medical System (CMS) is an innovation-driven specialty pharmaceutical company with a strong focus on marketing and sales in China. The...
113 Views
China Medical System Holdings Limited: Earnings Update
China Medical System (CMS) entered FY2025 with a clearer strategic direction than it had at initiation. The earlier debate was whether the company...
111 Views
APAC Healthcare Weekly (August 9) – Hengrui, CSPC Pharma, Takeda Pharma, Otsuka, Alteogen
Hengrui’s trastuzumab rezetecan got 3rd indication approval in China. CSPC and AstraZeneca form JV for biologics manufacturing facility in China....
122 Views